and their statistical power on smaller samples size. Furthermore, while cross-scales studies employ linear as well as complex non-linear analytical mathematics, multiscale ones have generally been deceivingly simple in terms of modeling, proposing one integrative approach regardless of the biomedical scale.
Indeed, the complexity of independently modeling each combination of two scales and thereafter the higher degree interactions for deep integration of n scales has not yet been attempted. Combinatorics informs us that such modeling grows exponentially with scale † .
Figure 1: Seminal integrative genomics analytics leading to predicting increasingly
difficult clinical outcome problems. Nine seminal methodological studies that led to the use of data fusion across four scales of 'omics data are presented in a timeline (x axis) according to four additional characteristics: the increasing difficulty of the clinical prediction (y axis), the level of data integration (shape), the number of 'omics scales integrated (size), the complexity of the clinical variable to predict (color). Full integration † The number of mathematical models required to specify each interaction between n scales of 'omics measurements increases as follows (note that combinations of higher order than binary are included, e.g. ternary, quaternary, etc.): Count of Interaction Models = (2 n -n -1).
Thus, for n=3,4, 5 or 6 scales, the number of interaction models required are 4, 11, 26, or 57, respectively. 
Predicting clinical outcome of complex disorders
Mendelian disorders can be diagnosed with a single genetic marker that also provides insight in the underpinning biological mechanisms. Predicting clinical outcome of complex diseases has conventionally leveraged this principle using single molecular biomarkers that are correlated with outcomes. In spite of a plethora of genomic studies, very few biomarkers have been discovered for complex disorders in the last Miska's pioneered multiscale corroborative methods for clinical classification (miRNA, mRNA, CNV) [14] , while Johnson's team was first to utilize them across four genomic scales (copy number variation, mRNA, microRNA and methylation) [15] . Sander's team pioneered the multiscale data fusion to predict time-to-recurrence of serous ovarian tumors (2011) [16] . They integrated four scales with Cox Lasso models (mRNA, microRNA, methylation and copy number variation). They were followed by several other multiscale data fusion models that built from The Cancer Genome Atlas (TCGA) datasets [17] (e.g. matrix factorization techniques [18] , integrated pathway scores [19, 20] , and mutual exclusivity [20, 21] ).
Kim et al classifies clinical prognosis by fusing four 'omics scales: mRNA expression, microRNA expression, copy number variation (CNV), and DNA methylation [7] . While graph-based semi-supervised learning (SSL) [22] Further, these approaches should be confirmed in prospective independent studies. SSL should be applied to therapeutic response prediction problems that remain a greater challenge than prognostic.
While the commercial application of omics classifiers will require cost-efficient solutions, a tradeoff is 
